Biofourmis vs Dozee

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Biofourmis employs 100-500 people, while Dozee has 50-200 employees.

Biofourmis has raised more in total funding at $445M, compared to Dozee's $20M — a gap of $425M.

Biofourmis holds the higher Awaira Score at 73/100, compared to Dozee's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 13-point gap that reflects meaningful differences in scale or traction.

Biofourmis was founded by Kuldeep Singh in 2015. Dozee was founded by Mudit Dandwate in 2015. Visit each company's profile on Awaira for a full founder biography.

Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting. Dozee: Dozee builds a contactless remote patient monitoring system that uses a ballistocardiography sensor placed under a mattress to continuously track heart rate, respiratory rate, blood pressure trends, and sleep quality, transmitting data to an AI analysis platform that generates clinical-grade early warning scores for hospital staff. The system requires no wearables or patient cooperation, enabling continuous monitoring for elderly patients, post-surgical recovery, and ICU step-down units.\n\nThe company raised approximately $20M in Series B funding and has deployed its monitoring systems across hospitals in India and internationally, with evidence of measurable reductions in deterioration events and ICU transfers through early warning. Dozee's central monitoring dashboard allows nursing staff to oversee multiple patients simultaneously with automated deterioration alerts.\n\nContinuous patient monitoring outside of ICU settings is an underserved clinical problem globally, and particularly acute in India where nurse-to-patient ratios in general wards are often insufficient for manual vital sign monitoring. Dozee's contactless approach and AI early warning capability address both the clinical quality and resource efficiency dimensions of this challenge.

Both Biofourmis and Dozee were founded in the same year — 2015. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Biofourmis has approximately 100-500 employees, while Dozee has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Biofourmis and Dozee are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.